Presentation is loading. Please wait.

Presentation is loading. Please wait.

MDSC population in patient peripheral blood.

Published byEustace Underwood Modified over 4 years ago

Similar presentations

Presentation on theme: "MDSC population in patient peripheral blood."— Presentation transcript:

1 MDSC population in patient peripheral blood.
MDSC population in patient peripheral blood. A, the percentage of CD11b+CD15+ MDSCs was analyzed by flow cytometry with lymphogating on Lin−CD14−HLA-DR− cells. Gating strategy and representative FACS dot plots of patients and healthy controls are presented. B, the percentages of MDSCs were compared between healthy controls and patients before NK-cell therapy (n = 5). C, the percentages of MDSCs from cohort 6 (n = 3) were compared before (D0H0) and after (D35) MG4101 injections (n = 3). D, changes in MDSC populations were monitored for 5 weeks. Yaewon Yang et al. Cancer Immunol Res 2016;4: ©2016 by American Association for Cancer Research

Download ppt "MDSC population in patient peripheral blood."

Similar presentations

Fig. 2. Comparison of the Th1/Th2 ratio and the percentages of Th1 and Th2 cells between normal and allergic individuals. (A) The Th1/Th2 ratio observed.

Fig. 2. Comparison of the Th1/Th2 ratio and the percentages of Th1 and Th2 cells between normal and allergic individuals. (A) The Th1/Th2 ratio observed.
Supplementary Figure S1

Supplementary Figure S1
Immunologic effects of F16-IL2 therapy.

Immunologic effects of F16-IL2 therapy.
Melanoma donor (MD) NK cells are functionally impaired/exhausted.

Melanoma donor (MD) NK cells are functionally impaired/exhausted.
by Venetia Bigley, Laura E. Spence, and Matthew Collin

by Venetia Bigley, Laura E. Spence, and Matthew Collin
Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.

Clinical response to F16-IL2 and LDAC in patients with AML bone marrow involvement. Clinical response to F16-IL2 and LDAC in patients with AML bone marrow.
Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.

Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.
Nonclassical monocytes are specifically depleted following M-CSFR inhibition and these cells are highest in PD-L1 expression in blood of mice during therapy.

Nonclassical monocytes are specifically depleted following M-CSFR inhibition and these cells are highest in PD-L1 expression in blood of mice during therapy.
Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.

Attenuated MDSC-suppressive activity and metastasis development in IDO-deficient mice is rescued by IL-6. Attenuated MDSC-suppressive activity and metastasis.
MP cells are generated from naïve cells in the periphery.

MP cells are generated from naïve cells in the periphery.
FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.

FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.
ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.
Gr-1+ MDSC in tumor-bearing mice produce IL-6.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.
Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.
Figure 1 Effect of DMF therapy on T cell subsets

Figure 1 Effect of DMF therapy on T cell subsets
d a c b CD8 CD3 CD4 CD62L HLA-DR CD57 10% 85% 11% 76% 19% 60% 36% 66%

d a c b CD8 CD3 CD4 CD62L HLA-DR CD57 10% 85% 11% 76% 19% 60% 36% 66%
Postoperative changes in blood monocyte subsets.

Postoperative changes in blood monocyte subsets.
Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.

Figure 1 Schematic overview of flow cytometry Schematic overview on the analysis of peripheral immune cells by flow cytometry. Schematic overview of flow.
FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.

FIP200 loss links to poor autophagy and high apoptosis in naïve T cells in tumor. FIP200 loss links to poor autophagy and high apoptosis in naïve T cells.
CD27 expression on bovine γδ and CD4 T cells ex vivo and in response to mitogen. CD27 expression on bovine γδ and CD4 T cells ex vivo and in response to.

CD27 expression on bovine γδ and CD4 T cells ex vivo and in response to mitogen. CD27 expression on bovine γδ and CD4 T cells ex vivo and in response to.

Similar presentations

Ads by Google